Sign In
Buy NRSN
$0.465
-0.0108 (-2.27%)
At Close: Jul 31, 2026
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS
08:30am, Wednesday, 04'th Dec 2024
In participants who received PrimeC from the start of the 18-month study compared to those initially on placebo before transitioning to PrimeC, disease progression was slowed by 33% (p=0.007), demons
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
08:30am, Monday, 02'nd Dec 2024
CAMBRIDGE, Mass. , Dec. 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
09:20am, Thursday, 21'st Nov 2024
CAMBRIDGE, Mass. , Nov. 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
08:30am, Monday, 28'th Oct 2024
Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success Parallel preparations in Canada: NeuroSense p
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
08:30am, Thursday, 24'th Oct 2024
Groundbreaking PARADIGM Trial Offers New Hope for ALS Treatment CAMBRIDGE, Mass. , Oct. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
09:15am, Tuesday, 15'th Oct 2024
Dossier submission planned for Q2 2025; regulatory decision expected by Q1 2026 Estimated potential market opportunity: peak of $100M to $150M in annual revenue Company aims to expand approval efforts
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
09:00am, Wednesday, 09'th Oct 2024
The preparations for the regulatory submission for early commercialization in Canada follows the positive Phase 2b trial results which show PrimeC reduces ALS disease progression by 36% and improves s
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting
09:00am, Monday, 07'th Oct 2024
CAMBRIDGE, Mass. , Oct. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
09:05am, Tuesday, 24'th Sep 2024
The Company's intellectual property now covers the combination, formulation, and method of use of PrimeC Patent protection extends through 2042, adding four additional years to PrimeC's IP umbrella CA
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
09:00am, Tuesday, 24'th Sep 2024
CAMBRIDGE, Mass. , Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
04:30pm, Friday, 30'th Aug 2024
CAMBRIDGE, Mass. , Aug. 30, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price
02:00pm, Wednesday, 07'th Aug 2024
CAMBRIDGE, Mass. , Aug. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial
09:15am, Thursday, 01'st Aug 2024
12-month data demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigation Previous results showed PrimeC slowed disease progression by 36% and improved survi
NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. , July 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
This cheap biotech offers investors a play on ALS if trial data continues to impress
12:34pm, Tuesday, 02'nd Jul 2024
NeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.
